title: The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymerase.
abstract: T-705 (Favipiravir) is a broad-spectrum antiviral molecule currently in late stage clinical development for the treatment of influenza virus infection. Although it is believed that T-705 potency is mediated by its ribofuranosyl triphosphate (T-705 RTP) metabolite that could be mutagenic, the exact molecular interaction with the polymerase of influenza A virus (IAVpol) has not been elucidated. Here, we developed a biochemical assay to measure the kinetics of nucleotide incorporation by IAVpol in the elongation mode. In this assay, T-705 RTP was recognized by IAVpol as an efficient substrate for incorporation to the RNA both as a guanosine and an adenosine analog. Compared to natural GTP and ATP, the discrimination of T-705 RTP was about 19- and 30-fold, respectively. Although the single incorporation of the ribonucleotide monophosphate form of T-705 did not efficiently block RNA synthesis, two consecutive incorporation events prevented further primer extension. In comparison, 3'-deoxy GTP caused immediate chain termination but was incorporated less efficiently by the enzyme, with a discrimination of 4,900-fold relative to natural GTP. Collectively, these results provide the first detailed biochemical characterization to evaluate the substrate efficiency and the inhibition potency of nucleotide analogs against influenza virus polymerase. The combination of ambiguous base-pairing with low discrimination of T-705 RTP provides a mechanistic basis for the in vitro mutagenic effect of T-705 towards influenza virus.
authors.affiliation: Alios BioPharma, Inc., South San Francisco, California, United States of America. zjin@aliosbiopharma.com
authors.forename: Zhinan
authors.initials: Z
authors.lastname: Jin
authors.forename: Lucas K
authors.initials: LK
authors.lastname: Smith
authors.forename: Vivek K
authors.initials: VK
authors.lastname: Rajwanshi
authors.forename: Baek
authors.initials: B
authors.lastname: Kim
authors.forename: Jerome
authors.initials: J
authors.lastname: Deval
mesh_terms: D000577:Amides / Q000378:metabolism / Q000494:pharmacology*; D000818:Animals; D000963:Antimetabolites / Q000378:metabolism / Q000494:pharmacology; D000998:Antiviral Agents / Q000378:metabolism / Q000494:pharmacology*; D020137:Base Pair Mismatch / Q000187:drug effects / Q000502:physiology; D020029:Base Pairing / Q000187:drug effects*; D004259:DNA-Directed DNA Polymerase / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D009980:Influenza A virus / Q000201:enzymology*; D011122:Polyphosphates / Q000378:metabolism / Q000494:pharmacology; D011719:Pyrazines / Q000378:metabolism / Q000494:pharmacology*; D012254:Ribavirin / Q000031:analogs & derivatives / Q000494:pharmacology; D061987:Sf9 Cells; D018411:Spodoptera; D013379:Substrate Specificity
chemical_list: D000577:Amides; D000963:Antimetabolites; D000998:Antiviral Agents; D011122:Polyphosphates; D011719:Pyrazines; D012254:Ribavirin; D004259:DNA-Directed DNA Polymerase; C462182:favipiravir; C005692:triphosphoric acid